BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38294283)

  • 1. The Impact of Four Smoking Metrics on Survival After Diagnosis with HPV+ Oropharyngeal Cancer.
    Wilkins SG; Shah R; Safranek CW; Shah HP; Mehra S
    Laryngoscope; 2024 Jul; 134(7):3158-3164. PubMed ID: 38294283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of smoking and outcomes in HPV-positive oropharyngeal cancer: A systematic review.
    Chen SY; Massa S; Mazul AL; Kallogjeri D; Yaeger L; Jackson RS; Zevallos J; Pipkorn P
    Am J Otolaryngol; 2020; 41(5):102592. PubMed ID: 32521295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the impact of smoking on disease-specific survival outcomes in patients with human papillomavirus-associated oropharyngeal cancer treated with transoral robotic surgery.
    Roden DF; Hobelmann K; Vimawala S; Richa T; Fundakowski CE; Goldman R; Luginbuhl A; Curry JM; Cognetti DM
    Cancer; 2020 Jan; 126(9):1873-1887. PubMed ID: 32032441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Smoking and Primary Tumor Subsite on Recurrence in HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Lee RH; Salesky M; Benjamin T; El-Sayed IH; George JR; Ha PK; Ryan WR; Heaton CM
    Otolaryngol Head Neck Surg; 2022 Apr; 166(4):704-711. PubMed ID: 34182836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes.
    Chen SY; Last A; Ettyreddy A; Kallogjeri D; Wahle B; Chidambaram S; Mazul A; Thorstad W; Jackson RS; Zevallos JP; Pipkorn P
    Am J Otolaryngol; 2021; 42(3):102915. PubMed ID: 33482566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma.
    Elhalawani H; Mohamed ASR; Elgohari B; Lin TA; Sikora AG; Lai SY; Abusaif A; Phan J; Morrison WH; Gunn GB; Rosenthal DI; Garden AS; Fuller CD; Sandulache VC
    BMC Cancer; 2020 Sep; 20(1):912. PubMed ID: 32967643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Smoking on Outcomes of HPV-related Oropharyngeal Cancer Treated with Primary Radiation or Surgery.
    Vawda N; Banerjee RN; Debenham BJ
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1125-1131. PubMed ID: 30513378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of Smoking in Human Papillomavirus-Positive Oropharyngeal Cancer Under American Joint Committee on Cancer Eighth Edition Stage.
    Chidambaram S; Nakken ER; Kennedy W; Thorstad WL; Chen SY; Pipkorn P; Zevallos JP; Mazul AL
    Laryngoscope; 2020 Aug; 130(8):1961-1966. PubMed ID: 32293733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation.
    Platek AJ; Jayaprakash V; Merzianu M; Platek ME; Cohan DM; Hicks WL; Marimuthu SP; Winslow TB; Gupta V; Arshad H; Kuriakose MA; Dibaj S; Marshall JR; Reid ME; Warren GW; Singh AK
    Laryngoscope; 2016 Dec; 126(12):2733-2738. PubMed ID: 27346612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis.
    Broughman JR; Xiong DD; Moeller BJ; Contrera KJ; Prendes BL; Lamarre ED; Ku JA; Burkey BB; Woody NM; Joshi NP; Adelstein DJ; Geiger JL; Frenkel CH; Milas ZL; Brickman DS; Sumrall AL; Carrizosa DR; Greskovich JF; Koyfman SA; Ward MC
    Cancer; 2020 Jun; 126(12):2784-2790. PubMed ID: 32167593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of High-Risk Pathologic Features in HPV-Related Oropharyngeal Squamous Cell Carcinoma and Tobacco Use.
    Kompelli AR; Morgan P; Li H; Harris W; Day TA; Neskey DM
    Otolaryngol Head Neck Surg; 2019 May; 160(5):855-861. PubMed ID: 30526292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of active smoking on outcomes in HPV+ oropharyngeal cancer.
    Xiao R; Pham Y; Ward MC; Houston N; Reddy CA; Joshi NP; Greskovich JF; Woody NM; Chute DJ; Lamarre ED; Prendes BL; Lorenz RR; Scharpf J; Burkey BB; Geiger JL; Adelstein DJ; Koyfman SA
    Head Neck; 2020 Feb; 42(2):269-280. PubMed ID: 31769100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effect of smoking on prognosis in human papillomavirus-associated oropharyngeal carcinoma.
    Liskamp CP; Janssens GO; Bussink J; Melchers WJ; Kaanders JH; Verhoef CG
    Head Neck; 2016 Dec; 38(12):1780-1787. PubMed ID: 27248701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
    Hu Q; Li F; Yang K
    PeerJ; 2024; 12():e17391. PubMed ID: 38784388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV Status and Survival in Non-Oropharyngeal Squamous Cell Carcinoma of the Head and Neck.
    Wookey VB; Appiah AK; Kallam A; Ernani V; Smith LM; Ganti AK
    Anticancer Res; 2019 Apr; 39(4):1907-1914. PubMed ID: 30952732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design.
    Fleming CW; Ward MC; Woody NM; Joshi NP; Greskovich JF; Rybicki L; Xiong D; Contrera K; Chute DJ; Milas ZL; Frenkel CH; Brickman DS; Carrizosa DR; Ku J; Prendes B; Lamarre E; Lorenz RR; Scharpf J; Burkey BB; Schwartzman L; Geiger JL; Adelstein DJ; Koyfman SA
    Oral Oncol; 2021 Jan; 112():105046. PubMed ID: 33129058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
    Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
    Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of the lymph node ratio as predictor of prognosis is higher in HPV-negative than in HPV-positive oropharyngeal squamous cell carcinoma.
    Meyer MF; Meinrath J; Seehawer J; Lechner A; Odenthal M; Quaas A; Semrau R; Huebbers CU; Marnitz S; Büttner R; Beutner D
    Clin Otolaryngol; 2018 Feb; 43(1):192-198. PubMed ID: 28714274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.